COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > New England Journal Of Medicine: Inflammation

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Aug 31, 2024 11:58am

526 Views

Post# 36204013

New England Journal Of Medicine: Inflammation

Today's New England Journal of Medicine.

This article supports call to extend the risk period for cardiovascular disease beyond 10 years. Importance of inflammation also supported.
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women | New England Journal of Medicine (nejm.org)

This would appear to support a potentially safe and well tolerated neutraceutical pill to treat early inflammation well in advance. Visionary Gilles Gagnon's oat beta glucan and avenanthramide chewy products as well as avenanthramide oat flour would also seem significant. Using Juvente on the skin daily may also help address systemic inflammation. This company has a potential multi-product program for complete oat care as the importance of inflammation grows in recognition.

@EricTopol

Beyond LDL cholesterol, the importance of inflammation (as reflected by hs-CRP) and Lp(a) for determining risk of adverse cardiovascular outcomes in a 30-year study of ~28,000 healthy women